Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Tom Sawyer Perspectives 13.6 Delivers Faster, More Flexible Knowledge Graph Visualization Aviation
  • Mayhew Tools Expands Cable Tie Line with Mounting Hole Cable Ties and Mounting Pads Aviation
  • War Day 619: Zelensky or Zaluzhny –  – Who is Closer to Reality?
    War Day 619: Zelensky or Zaluzhny – – Who is Closer to Reality? World News
  • Expect Surging Growth with Rising Demand for Vegan Diets Business
  • War Day 296: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin
    War Day 296: war diaries w/Advisor to Ukraine President, Intel Officer @arestovych & #Feygin World News
  • Pinpoint Labs Unveils SharePoint Collector V6, a Streamlined Solution for Efficient Data Collection Business
  • Music Historian Dr. Don Cusic Delivers Definitive Biography of Chet Atkins World News
  • Secretary Blinken’s Call with Moroccan Foreign Minister Bourita World News

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Posted on December 22, 2022 By NewsEditor
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery PlatformGb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery PlatformGb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

LAS VEGAS - December 22, 2022 - (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses. 

The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences' CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.

"Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself," said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics"; download it here. 

A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences' proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences' MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes," and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.


Contact Information:
Alexis Quintal
[email protected]


Press Release Service by Newswire.com

Original Source: Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Business

Post navigation

Previous Post: Following More Than a Decade of Development, TM Technologies Demonstrates More Than 50% Increase in Data Efficiency for Telecom
Next Post: Announcing the launch of pixiv’s time-limited event ‘myBESTpixiv2022’, where users can look back on and share their activities over the past year

Related Posts

  • ShipWise Launches ShipWise Intelligence to Power Smarter, Leaner Shipping Operations Business
  • San Diego Youth Non-Profit Tech-Angels Bridges Generational Gaps with Technology and Tutoring for Senior Veterans Business
  • CellPay and Klarna Have Partnered to Offer Consumers More Flexible Payment Options Business
  • Grand Valley Garage Doors Celebrates Installation of Over 5,000 Clopay Doors Since 2008 Business
  • Henderson Auctions Holds Bank-Seized Collector Car Auction Business
  • New Data From InnoLead Shows Nearly 70 Percent of Respondents at Large Corporations Expect Startup Engagement Activity to Increase in 2023 Business
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • The Assistive Technologies Market for Visually Impaired Expected to Reach $12.71 Billion by 2030November 19, 2026
  • Sabio Group hires Simon Foot to lead Sabio Consulting as AI-first Transformation AcceleratesNovember 19, 2026
  • Atenolol Market Outlook Report Including Segment Analysis and Strategic Industry InsightsNovember 18, 2026
  • Abdullah Al Junayed Releases Open Research Dataset on Machine FatigueNovember 18, 2026
  • The At-Home Genetic Testing Market Is Projected to Grow at a 15.5% CAGR by 2030November 17, 2026
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Gossip Stone TV Announces the Arrival of Isa Bagirov, the Master Mentalist for the “Hypno Challenge” Show World News
  • Secretary Blinken’s Call with Greek Foreign Minister Dendias World News
  • Luliang Highland Vegetables by Tian Rui Ling Dong Wins Iron A’ Design Award in Graphics and Visual Communication Design Business
  • ArtVersion Honored With Two Prestigious Awards by the Academy of Interactive & Visual Arts Business
  • Triangle IV Hydration & Wellness and 1st Choice Homecare & Infusion Services Announce Grand Opening in Johnston County Business
  • Best Six Sigma Certification Resources Aggregated by Management and Strategy Institute Aviation
  • Space Force Association Announces Strategic Corporate Partnerships with Google & Mercury Systems to Advance Spacepower Aviation
  • VDO.AI’s Innovative Technology-Led Campaign for The NBA Earns Shortlist at The Drum Awards for Marketing Americas 2023
    VDO.AI’s Innovative Technology-Led Campaign for The NBA Earns Shortlist at The Drum Awards for Marketing Americas 2023 World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2026 195 News. All Rights Reserved by Coolaser

Powered by .